ProCE Banner Activity

My Thoughts on the Recent FDA Approval of Acalabrutinib in CLL

Clinical Thought
Acalabrutinib is now approved for treating patients with CLL. Are you ready to incorporate it into your practice?

Released: January 10, 2020

Expiration: January 08, 2021

No longer available for credit.

Share

Faculty

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Pharmacyclics AbbVie

Verastem Oncology

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Celgene, Genentech, Gilead Sciences, Janssen, and Pharmacyclics.